bimekizumab
Bimzelx (bimekizumab) is a dual IL-17A and IL-17F inhibitor from UCB that neutralises two closely related cytokines driving inflammation in skin, joints, and spine. It treats moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa in adults.
This page is based on EMA, FDA, and DailyMed prescribing information for bimekizumab; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
In psoriasis and related diseases, immune cells release two related alarm chemicals — IL-17A and IL-17F — that tell the skin to thicken, joints to swell, and hair follicles to become inflamed. Most drugs block only one of these alarms. Bimekizumab blocks both: by neutralising IL-17A and IL-17F together, it silences a wider range of the inflammatory signal, so skin plaques clear more completely and joint and spine inflammation eases.
In simple terms
Bimekizumab is an injection that blocks two inflammatory proteins called IL-17A and IL-17F. These proteins are released by overactive immune cells and tell skin cells to grow too fast, joint linings to swell, and hair follicles to become inflamed. By neutralising both, bimekizumab clears skin plaques in psoriasis, reduces joint pain in psoriatic arthritis, eases spinal inflammation in ankylosing spondylitis and non-radiographic axial spondyloarthritis, and reduces the painful lumps and tunnels of hidradenitis suppurativa.
In depth
Bimekizumab is a humanised IgG1 monoclonal antibody that selectively neutralises both interleukin-17A and interleukin-17F, two cytokines that share ~50% amino-acid sequence identity and signal through the same IL-17RA/IL-17RC receptor complex. IL-17A and IL-17F activate Act1-TRAF6, driving NF-κB, MAPK, and C/EBPβ to induce chemokines (CXCL1, CXCL8), antimicrobial peptides (S100A7, S100A8, S100A9, β-defensins), and matrix metalloproteinases that sustain neutrophilic inflammation. By binding both ligands with high affinity, bimekizumab achieves broader pathway suppression than IL-17A-only inhibitors. This dual blockade underlies its efficacy across plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa — conditions in which both IL-17A and IL-17F contribute to pathogenesis.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How bimekizumab neutralises both IL-17A and IL-17F
- In psoriasis and related diseases, immune cells release two related alarm chemicals — IL-17A and IL-17F — that tell the skin to thicken, joints to swell, and hair follicles to become inflamed.
- Most drugs block only one of these alarms. Bimekizumab blocks both: by neutralising IL-17A and IL-17F together, it silences a wider range of the inflammatory signal, so skin plaques clear more completely and joint and spine inflammation eases.
- Bimekizumab is a humanised IgG1 monoclonal antibody that selectively neutralises both interleukin-17A and interleukin-17F, two cytokines that share ~50% amino-acid sequence identity and signal through the same IL-17RA/IL-17RC receptor complex.
- By binding both ligands with high affinity, bimekizumab achieves broader pathway suppression than IL-17A-only inhibitors.
Target: Interleukin-17A and Interleukin-17F
Two closely related pro-inflammatory cytokines produced by Th17 cells, γδ T cells, and ILC3s; both signal through the IL-17RA/IL-17RC receptor complex to drive keratinocyte hyper-proliferation, neutrophil recruitment, and chronic inflammation in skin, joints, and hair follicles.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
- Treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more DMARDs, alone or in combination with methotrexate
- Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have responded inadequately or are intolerant to NSAIDs
- Treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy
- Treatment of active moderate to severe hidradenitis suppurativa in adults with an inadequate response to conventional systemic HS therapy
Approved uses in United States
FDA- Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis in adults
- Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
- Active ankylosing spondylitis in adults
- Moderate to severe hidradenitis suppurativa in adults
Approved uses in United States
DailyMed- Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis in adults
- Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
- Active ankylosing spondylitis in adults
- Moderate to severe hidradenitis suppurativa in adults
Official sources
The statements on this page trace back to these records.
- Bimzelx (bimekizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: BIMZELX prescribing information
U.S. Food and Drug Administration
- DailyMed: BIMZELX prescribing information
DailyMed, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.